Traditional therapies of Zhuang medicine improve pain and joint dysfunction of patients in rheumatoid arthritis

A protocol for systematic review and meta-analysis

Yehao Luo, MSa, Donghan Xu, MSb, Zhiyong Cao, MSc, Qiu Xia Chen, MSd, Lizi Shen Wang, MDd, Gang Fang,∗, Yuzhou Pang

Abstract

Background: Rheumatoid arthritis (RA) is a common chronic inflammatory autoimmune disease, which can lead to joint destruction, dysfunction, finally deformity. Currently, Western medicine treats it with disease-modifying antirheumatic drugs, NSAIDs, glucocorticoid, biological agents, etc, which can induce adverse drug reactions. And now, as an important mean of treating RA, Zhuang medicine has been widely used in clinics, and has achieved significant efficacy.

Methods and analysis: The following databases will be searched for relevant information before July 2020: PubMed, Embase, Cochrane Library, Web of Science, and China National Knowledge Infrastructure. Major results: levels of C-reactive protein, erythrocyte sedimentation rate, Rheumatoid factor. Secondary results: morning stiffness time, range of motion, arthralgia, joint tenderness index, joint swelling index, total effective rate, adverse event. Data will be collected independently by 2 researchers, and the risk of bias in meta analysis will be evaluated according to “Cochrane Handbook for Systematic Reviews of Interventions”. All data analysis will be conducted using Review Manager V.5.3. and Stata V.12.0.

Results: The curative effect and safety of traditional therapies of Zhuang Medicine treatment for RA patients will be evaluated systematically.

Conclusion: The systematic review of this study will summarize the currently published evidence of traditional therapies of Zhuang Medicine treatment for RA to further guide its promotion and application.

Abbreviations: DMARDs = disease-modifying antirheumatic drugs, RA = rheumatoid arthritis, RCT = randomized controlled trial.

Keywords: joint dysfunction, pain, protocol, rheumatoid arthritis, systematic review, Zhuang medicine

1. Introduction

Rheumatoid arthritis (RA), as known to all, is a long-lasting disease that primarily affects the joints.[1] Also, it is characterized by an aggressive inflammatory reaction of the small joints of the hand and foot, often accompanied by a positive serum rheumatoid factor, which can lead to joint deformity and dysfunction.[2] However, the cause of RA is unclear, but genetic and environmental factors are involved.[3] It is reported that the immune system affected by certain conditions could attack the
joints. To the patients, RA has a significant negative impact on the daily activities, including work and household tasks, and health-related quality of life, even it increases mortality. Globally, RA affects about 0.5 to 1 percent of adults in the developed countries, and it is more occupied in women at the middle age. Therefore, it is necessary to relieve the symptoms of RA, even cure. Modern Western Medicine mainly treats RA with traditional disease-modifying anti-rheumatic drugs (DMARDs), biologic agents, tofacitinib, glucocorticoids and treat-to-target approach. But partial patients unfortunately have to suffer from gastrointestinal adverse reactions which are induced by DMARDs, and a high price of the treatments that could add up the burden on the family.

Unexpectedly, we found that the treatment of traditional Chinese Medicine has a great impact on RA, not only relieve the pain and joints dysfunction but also raise the health-life quality. Have to commit, Zhuang medicine is one kind of treatments of traditional Chinese medicine. According to Zhuang medicine, RA belongs to range of “Fungcaep” (a unique term used in Zhuang medicine). The guideline for the treatments of RA is based on the theory of Zhuang medicine, moreover, the use of medicated thread moxibustion, cupping therapy with Zhuang medicine, exsanguinante therapy and other treatments with Zhuang medicine have been applied in clinics, which obtain an outstanding clinical efficiency. However, there is a lack of evidence of results of traditional therapies of Zhuang Medicine in treating RA. Therefore, the paper will evaluate the effectiveness and safety of traditional therapies of Zhuang medicine treatment for RA. This review will be the first evaluation of the impact of traditional therapies of Zhuang medicine treatment.

2. Objectives

In a randomized controlled trial (RCT), the efficacy and side effects of traditional therapies of Zhuang medicine in treating RA have been evaluated systematically. We expect to provide reference for RA treatment in the field of traditional Chinese medicine.

3. Methods

3.1. Study registration

The protocol of the systematic review has been registered. Registration: OSF Preregistration.2020, Aug.19. osf.io/c4xv3/. This systematic review protocol will be conducted and reported strictly according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines, and the important protocol amendments will be documented in the full review.

3.2. Inclusion and exclusion criteria for study selection

3.2.1. Inclusion criteria. Inclusion criteria are all RCTs, which main treatment of RA is traditional therapies of Zhuang medicine. The language of the trials to be included only Chinese or English.

3.2.2. exclusion criteria. Following studies will be excluded.

1. Repeated publications
2. Review of literature and cases
3. Animal studies
4. Incomplete literature
5. Non-RCT

3.3. Types of participants

We will include RCTs of participants of 18 years or older, of any sex, race/ethnicity, and the patients are in accordance with diagnostic criteria of RA established by the American College of Rheumatology (ACR) in 1987 or the European alliance against Rheumatism (EULAR)/ACR in 2009 or the Chinese institute of Rheumatology in 2010 or the World Health Organization (WHO) in 2008. We will exclude advanced stage patients, severe joint deformities, and grade IV joint function; patients who are also participating in clinical trials for other drugs or treatments; patients with mental or legal disabilities should not be treated with this therapy; overlap other rheumatic diseases, such as systemic lupus erythematosus, Sjogren syndrome, severe knee osteoarthritis, etc; pregnant or lactating women, mental patients, etc; patients with severe diseases of the heart, brain, liver, kidney, or hematopoietic system.

3.4. Interventions and controls

Interventions included treatment with traditional therapies of Zhuang medicine. The control group only received conventional western medicine treatment. The routine treatment of each RCT may not be identical, but the use of traditional therapies of Zhuang medicine is the only difference between intervention and control.

3.5. Type of outcome measures

3.5.1. Main outcomes.

1. C-reactive protein;
2. erythrocyte sedimentation rate;
3. rheumatoid factor

3.5.2. Additional outcomes.

1. morning stiffness time;
2. range of motion;
3. arthralgia;
4. joint tenderness index;
5. joint swelling index;
6. total effective rate;
7. adverse events.

3.6. Search methods

3.6.1. Search resources. This review will include the following electronic databases from their inception to July 2020: Electronic databases will be used the same (Table 1). Other electronic data bases will be used the same strategy.
3.7. Data collection and analysis

3.7.1. Studies selection. There will be 2 researchers (YL and DX) carry out the selection of research literature independently using endnote x9 software. We will first make the preliminary selection by screening titles and abstracts. Secondly, we will download full text of the relevant studies for further selection according to the inclusion criteria. If there is any different opinion, 2 researchers will discuss and reach an agreement. If a consensus could not be reached, there will be a third researcher (GF) who make the final decision. The details of selection process will be displayed in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart.

3.7.2. Assessment of risk of bias. The assessment of risk of bias will be carried out by 2 independent reviewers (YL and WLQ), using the Cochrane Collaboration’s “Risk of bias” tool. Study bias will be conducted as either: “unclear,” “low,” or “high” risk for the following criteria: random sequence generation, allocation concealment, blinding, incomplete data, selective outcome reporting, and other bias. The assessment of the bias has caused...
Table 1
Search strategy in PubMed database.

| #1 | Randomized controlled trial [title/abstract] |
| #2 | Controlled clinical trial [title/abstract] |
| #3 | Randomized [title/abstract] |
| #4 | Randomly [title/abstract] |
| #5 | Trial [title/abstract] |
| #6 | #1 or #2 or #3 or #4 or #5 |
| #7 | Rheumatoid arthritis [title/abstract] |
| #8 | Chronic infectious arthritis [title/abstract] |
| #9 | #7 or #8 |
| #10 | Zhuang medicine thread moxibustion [title/abstract] |
| #11 | Zhuang medicine bamboo cupping therapy [title/abstract] |
| #12 | Zhuang medicine fire needle [title/abstract] |
| #13 | Zhuang medicine needle prickling therapy [title/abstract] |
| #14 | Zhuang medicine hot-sensitive point-probing acupuncture therapy [title/abstract] |
| #15 | #10 or #11 or #12 or #13 or #14 |
| #16 | #6 or #9 or #15 |

In the treatment of Zhuang medicine in RA, it has been assumed that there is a need for discussion with a third reviewer (PYZ). The graphic representations of potential bias within and across studies using Rev Man V.5.3.5.

3.7.3. Measures of treatment effect. Statistical analyses will be conducted using the risk ratio with 95% confidence intervals. Odds ratio and relative risk are commonly used for dichotomous outcomes data. For continuous outcomes, the weighted mean difference or the standard mean difference (SMD) will be analyzed.

3.7.4. Unit of analysis issues. The unit of analysis will be the individual participant.

3.7.5. Dealing with missing data. Among the results of several studies with insufficient data or missing data, the corresponding author will be contacted to complement the contents. If the corresponding author cannot be contacted, the data alone will be conducted.

3.7.6. Assessment of heterogeneity. The assessment of heterogeneity will be conducted by Review Manager (V.5.3.5). Chi-squared test and I2value of the forest plot, will be calculated to assess heterogeneity, according to the Cochrane Handbook. The I2 value is classified into 4 levels: little or no heterogeneity (0%–40%), moderate heterogeneity (30%–60%), substantial heterogeneity (50%–90%), and considerable heterogeneity (75%–100%).

3.7.7. Assessment of reporting biases. If the numbers of available studies are sufficient, funnel plots will be assessed reporting biases.

3.7.8. Data synthesis. Review Manager (V.5.3.5) will be used to analyze. The test indicated little or no heterogeneity; a fixed effect model will be used for data. The random effect model will be adopted when there is considerable heterogeneity (I2 ≥ 50%). If there is considerable variation in results (I2 ≥ 75%), the meta-analysis will not be performed. The narrative and qualitative summary will be available.

3.7.9. Subgroup analysis and investigation of heterogeneity. Subgroup analysis will be conducted to assess heterogeneity. The different types of auricular acupuncture (embedding therapy on ear point, auricular point seeds pressure, bloodletting at auricular points, auricular point on auto chemotherapy) may be affected heterogeneity.

3.7.10. Sensitivity analysis. Sensitivity analysis will be used to assess the robustness of the results. It is possible to determine according to methodological quality, sample size, and analysis-related issues. The studies that follow a sequence will be removed from all the inclusion reviews. The Chi-squared test and I2 value will be used to quantify statistical heterogeneity.

3.7.11. Summary of evidence. The assessment of evidence for all outcomes will be summarized using the Grading of Recommendations Assessment, Development and Evaluation approach. The quality of evidence will be rated as high, moderate, low, and very low quality.

4. Discussion

Globally, treatments of RA is a difficult but important problem in the medical field. In Western medicine, treatments of RA emphasize on “target therapy”, with a preference to relieve symptoms. Most patients are treated with non-steroidal anti-inflammatory drugs, DMARDs and biological agents, however, these drugs have serious side effects such as hepatorenal toxicity and immunosuppression, and biological agents are costly so that it could be a financial burden on family.[9][10] Zhuang medicine, as a part of traditional Chinese medicine, has a complete theoretical system and abundant clinical experience. Moreover, various treatments have a remarkable curative effects in RA. According to the theory of Zhuang medicine, there is a unique understanding of RA, which belongs to the category of Fungcaep (a special term used in Zhuang medicine).[11] According to the theory of Zhuang medicine, it is mostly caused by pathogenic toxin, physical weakness, emotional disorder and so on. In fact, the essence of pathogenesis is “Shi Du” (dampness toxin). Up to now, the therapies of Zhuang medicine are various, which mainly contains of Zhuang medicine thread moxibustion, Zhuang medicine bamboo cupping therapy, Zhuang medicine fire needle, Zhuang medicine needle prickling therapy, Zhuang medicine hot-sensitive point-probing acupuncture therapy and so on.

The treatment of Zhuang medicine in RA has been widely applied in clinics, which obtains a great effect. It is reported that, for instance, Zhuang medicine cupping combined with prickling blood therapy can improve the clinical symptoms of arthralgia disease patients significantly (Zeng et al 2008).[12] Besides, Zhuang medicine thread Moxibustion can obviously reduce the levels of serum tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (Xu et al 2014).[13] Through many clinical samples, it is fully realized that Zhuang medicine has its advantages in treating RA, even in curative effects, it is greater than Western medicine, with fewer adverse reactions.

However, the mechanism and standards of treating RA using traditional therapies of Zhuang Medicine are not expounded systematically. In short, this systematic review and meta-analysis can help identify the potential value of Zhuang Medicine in treating RA and improving pain, joint dysfunction and life quality. This study can provide a foundation for the release of RA treatment guidelines and treatment options of RA patients, and thus benefit more patients.

Author contributions

Conceptualization: Yehao Luo, Donghan Xu.
Data curation: Donghan Xu, Quxia Chen, Fang Gang.
Data curation: Yehao Luo.
Formal analysis: Yehao Luo, Zhiyong Cao, Lizhen Wang, Donghan Xu.

Funding acquisition: Yuzhou Pang, Fang Gang.

Investigation: Qiuxia Chen, Lizhen Wang, Donghan Xu.

Methodology: Zhiyong Cao.

Project administration: Gang Fang, Yuzhou Pang.

Quality assessment: Fang Gang, Yehao Luo.

Resources: Donghan Xu, Lizhen Wang.

Software: Qiuxia Chen, Donghan Xu, Lizhen Wang, Zhiyong Cao.

Supervision: Yehao Luo.

Validation: Yehao Luo, Lizhen Wang.

Writing – original draft: Yehao Luo, Donghan Xu, Zhiyong Cao, Gang Fang.

Writing – review & editing: Donghan Xu, Fang Gang, Yuzhou Pang.

References

[1] Bergot AS, Giri R, Thomas R. The microbiome and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2019;33:101497.

[2] Handout on health: rheumatoid arthritis. national institute of arthritis and musculoskeletal and skin diseases. August 2014 [July 2, 2015]

[3] Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094–108.

[4] Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;CD008794.

[5] Jasvinder A. Singh, 1 Kenneth G. Saag, 1 S. Louis Bridges Jr. et al, 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Rheumatol, 68, 2016, 1–26.

[6] Jiang Yuping, Lao Kong, Ma Gao Feng, et al. Effect of moxibustion on synovialcytes apoptosis in adjuvant arthritis rats. Lishuzhen Medicine And Materia Medica Research 2017;28:

[7] Huang A, Pang Y, Tang Q, et al. Zhongguo Zhen Jiu 2018;38:243–50.

[8] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647–17647.

[9] McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328–37.

[10] Ramiro S, Sepezano A, Charzdionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101–36.

[11] Xing Sha, Pang yu Chau. Effects of Longzuan Tongbi decoction on anti-inflammatory factors IL-4 and IL-10 in experimental arthritis rats. Chin J Ethnic Med 2013.

[12] Zeng Zhendong, Wei Tao, Wei Xiuzhen, et al. Clinical study on the treatment of arthralgia disease with Zhuang medicine cupping and acupuncture therapy J. Sichuan Tradit Chinese Med 2008;7:106–8.

[13] Xu Hong, Guan Jianguo, Xiao Jing, et al. Effect of moxibustion on Zhaung medicine thread on serum tumor necrosis factor and Interleukin 1 in patients with rheumatoid arthritis j. Chin J Tradit Chin Med 2014;3202:332–4.